| Literature DB >> 30791220 |
Sho Fujiwara1, Yuriko Saiki1, Kota Ishizawa1, Shinichi Fukushige1, Mie Yamanaka1, Masaki Sato1,2, Masaharu Ishida2, Fuyuhiko Motoi2, Michiaki Unno2, Akira Horii1.
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is the most lethal cancer, mainly because of its invasive and metastatic characteristics. Pancreatic intraepithelial neoplasia (PanIN) is one of the major precursor lesions of PDAC. Although epithelial-to-mesenchymal transition (EMT) is known to play an important role for these malignant behaviors, the association between PanIN and EMT has not been clearly understood. Therefore, we explored possible molecules for regulation of EMT immunohistochemically. Using surgically resected specimens from 71 PDAC patients, expressions of SNAIL, SLUG, TWIST1, and ZEB1 were investigated in high-grade PanIN (HG-PanIN) and PDAC. Results demonstrated that PDAC accompanied by SNAIL-positive HG-PanIN showed a significantly better relapse-free survival (RFS) (median survival time (MST) of 11.3 months vs 4.4 months, P < 0.001) and overall survival overall survival (OS) (MST of 25.2 months vs 13.6 months, P < 0.001). In PDAC accompanied by SLUG-positive HG-PanIN, RFS and OS (P = 0.09 and P = 0.05) tended to have a better prognosis. In contrast, we could not find any significant prognostic benefits in the expression of TWIST1 or ZEB1 in PDAC accompanied by HG-PanIN. Our present results suggest that (1) EMT may play an important role in the development of PDAC from HG-PanIN, and (2) SNAIL may predict a distinct subgroup that shows a better prognosis.Entities:
Keywords: epithelial-to-mesenchymal transition; high-grade PanIN; pancreatic ductal adenocarcinoma; pancreatic intraepithelial neoplasia; prognosis
Mesh:
Substances:
Year: 2019 PMID: 30791220 PMCID: PMC6488215 DOI: 10.1002/cam4.2016
Source DB: PubMed Journal: Cancer Med ISSN: 2045-7634 Impact factor: 4.452
HG‐PanIN patients’ characteristics
| Age | |
| Average | 71 |
| Range | 58‐82 |
| Gender | |
| Male | 14 |
| Female | 13 |
| Operation | |
| Pancreaticoduodenectomy | 15 |
| Distal pancreatectomy | 8 |
| Total pancreatectomy | 4 |
| UICC stage | |
| IB | 1 |
| IIA | 4 |
| IIB | 9 |
| IV | 13 |
| UICC T | |
| 1 | 0 |
| 2 | 1 |
| 3 | 25 |
| 4 | 1 |
| UICC N | |
| 0 | 5 |
| 1 | 22 |
| UICC M | |
| 0 | 18 |
| 1 | 9 |
| ly | |
| 0 | 1 |
| 1 | 2 |
| 2 | 16 |
| 3 | 8 |
| v | |
| 0 | 1 |
| 1 | 5 |
| 2 | 15 |
| 3 | 6 |
| ne | |
| 0 | 1 |
| 1 | 3 |
| 2 | 4 |
| 3 | 19 |
Figure 1Immunohistochemical staining results of EMT regulators in HG‐PanIN: SNAIL, SLUG, TWIST1, and ZEB1. We categorized and defined three grades: grade 0, <10% positive staining; grade 1, 10%‐50% positive; grade 2, 50%< positive
Figure 2Expression of SNAIL and SLUG in HG‐PanIN and PDAC. Expression levels in PDAC regions were higher than those in HG‐PanIN, and expressions in invading PDAC regions are prominent
Figure 3Expression levels of EMT regulators and relationships between HG‐PanIN and PDAC. All regulators’ expressions increased in PDAC compared with HG‐PanIN. There were statistically significant differences in SNAIL and SLUG, respectively
Expression levels of EMT regulators in HG‐PanIN and PDAC lesions
| HG‐PanIN | PDAC | |||||
|---|---|---|---|---|---|---|
| Grade 0 | Grade 1 | Grade 2 | Grade 0 | Grade 1 | Grade 2 | |
| <10% | 10‐50% | 50%< | <10% | 10‐50% | 50%< | |
| SNAIL | 4/27 (14.8%) | 11/27 (40.7%) | 12/27 (44.4%) | 2/27 (7.4%) | 3/27 (11.1%) | 22/27 (81.5%) |
| SLUG | 8/27 (29.6%) | 9/27 (33.3%) | 10/27 (37.0%) | 1/27 (3.7%) | 10/27 (37.0%) | 16/27 (59.3%) |
| TWIST1 | 18/27 (66.7%) | 4/27 (14.8%) | 5/27 (18.5%) | 14/27 (51.9%) | 10/27 (37.0%) | 3/27 (11.1%) |
| ZEB1 | 25/27 (92.6%) | 2/27 (7.4%) | 0/27 (0.0%) | 22/27 (81.5%) | 5/27 (18.5%) | 0/27 (0.0%) |
EMT status in HG‐PanIN and clinicopathological features. There were any statistically significant differences between EMT positive groups and negative groups
| SNAIL | SLUG | TWIST1 | ZEB1 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Negative (n = 4) | Positive (n = 23) |
| Negative (n = 8) | Positive (n = 19) |
| Negative (n = 18) | Positive (n = 9) |
| Negative (n = 25) | Positive (n = 2) |
| ||
| Age | 0.96 | ||||||||||||
| 70 | 2 (50.0) | 11 (47.8) | 0.94 | 4 (50.0) | 9 (47.4) | 0.9 | 9 (50.0) | 4 (44.4) | 0.79 | 12 (52.0) | 1 (50.0) | ||
| 71 | 2 (50.0) | 12 (52.2) | 4 (50.0) | 10 (52.6) | 9 (50.0) | 5 (44.4) | 13 (52.0) | 1 (50.0) | |||||
| Gender | |||||||||||||
| Female | 1 (25.0) | 12 (52.2) | 0.32 | 4 (50.0) | 9 (47.4) | 0.9 | 10 (55.6) | 3 (33.3) | 0.28 | 13 (52.0) | 0 (0.0) | 0.16 | |
| Male | 3 (75.0) | 11 (47.8) | 4 (50.0) | 10 (52.6) | 8 (44.4) | 6 (66.7) | 12 (48.0) | 2 (100.0) | |||||
| UICC T | |||||||||||||
| T1,2 | 0 (0.0) | 1 (4.3) | 0.57 | 1 (12.5) | 0 (0.0) | 0.12 | 1 (5.6) | 0 (0.0) | 0.36 | 1 (4.0) | 0 (0.0) | 0.69 | |
| T3,4 | 4 (100.0) | 22 (95.7) | 7 (87.5) | 19 (100.0) | 17 (94.4) | 9 (100.0) | 24 (96.0) | 2 (100.0) | |||||
| UICC N | |||||||||||||
| N0 | 1 (25.0) | 4 (17.4) | 0.73 | 1 (12.5) | 4 (21.0) | 0.59 | 4 (22.2) | 1 (11.1) | 0.47 | 5 (20.0) | 0 (0.0) | 0.36 | |
| N1 | 3 (75.0) | 19 (82.6) | 7 (87.5) | 15 (79.0) | 14 (77.8) | 8 (88.9) | 20 (80.0) | 2 (100.0) | |||||
| UICC M | |||||||||||||
| M0 | 3 (75.0) | 15 (65.2) | 0.7 | 4 (50.0) | 14 (73.7) | 0.23 | 12 (66.7) | 6 (66.7) | 1 | 17 (68.0) | 1 (50.0) | 0.61 | |
| M1 | 1 (25.0) | 8 (24.8) | 4 (50.0) | 5 (26.3) | 6 (33.3) | 3 (33.3) | 8 (32.0) | 1 (50.0) | |||||
| Vascular invasion | |||||||||||||
| v0,1 | 0 (0.0) | 3 (13.0) | 0.31 | 1 (12.5) | 2 (10.5) | 0.88 | 3 (16.7) | 0 (0.0) | 0.12 | 3 (12.0) | 0 (0.0) | 0.48 | |
| v2,3 | 4 (100.0) | 20 (87.0) | 7 (87.5) | 17 (89.5) | 15 (83.3) | 9 (100.0) | 22 (88.0) | 2 (100.0) | |||||
| Lymphatic invasion | |||||||||||||
| ly0.1 | 1 (25.0) | 5 (21.7) | 0.89 | 1 (12.5) | 5 (26.3) | 0.41 | 5 (27.8) | 1 (11.1) | 0.3 | 5 (20.0) | 1 (50.0) | 0.37 | |
| ly2,3 | 3 (75.0) | 18 (78.3) | 7 (87.5) | 14 (73.7) | 13 (72.2) | 8 (88.9) | 20 (80.0) | 1 (50.0) | |||||
| Neural invasion | |||||||||||||
| ne0,1 | 0 (0.0) | 4 (17.4) | 0.37 | 2 (25.0) | 2 (10.5) | 0.35 | 4 (22.2) | 0 (0.0) | 0.058 | 3 (12.0) | 1 (50.0) | 0.22 | |
| ne2,3 | 4 (100.0) | 19 (82.6) | 6 (75.0) | 17 (89.5) | 14 (77.8) | 9 (100.0) | 22 (88.0) | 1 (50.0) | |||||
| Surgical resectability status | |||||||||||||
| R0 | 4 (100.0) | 19 (82.6) | 0.24 | 8 (100.0) | 15 (79.0) | 0.16 | 16 (88.9) | 7 (77.8) | 0.44 | 21 (84.0) | 2 (100.0) | 0.41 | |
| R1 | 0 (0.0) | 4 (17.4) | 0 (0.0) | 4 (21.0) | 2 (11.1) | 2 (22.2) | 4 (16.0) | 0 (0.0) | |||||
Figure 4Kaplan‐Meier survival curves by expression status of each EMT regulator in accompanying HG‐PDAC and patients’ prognoses. (A‐D) RFS; and (E‐H) OS. SNAIL (A and E), SLUG (B and F), TWIST1 (C and G), ZEB1 (D and H)